Verrica Pharmaceuticals Inc

Verrica Pharmaceuticals is a therapeutics company focused on developing and commercializing medications for dermatological diseases, including skin cancers. Its commercial product, YCANTH (VP-102), is a proprietary drug-device combination containing a GMP-controlled formulation of cantharidin delivered via a single-use applicator, and is the first and only healthcare professional-administered treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum — a highly contagious viral skin infection affecting approximately six million people in the United States, primarily children. YCANTH is also approved for molluscum contagiosum in Japan through a collaboration with Torii Pharmaceutical. The company is conducting a global Phase 3 clinical program studying YCANTH for the treatment of common warts in the U.S. and Japan, which represents the largest remaining unmet need in medical dermatology. Verrica also holds a worldwide license from Lytix Biopharma ASA for VP-315 (ruxotemitide), a novel oncolytic peptide in development for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. Approximately 250 million lives are eligible to receive YCANTH covered by insurance in the U.S. Updated Aug 6, 2026